Evaluation of Basal Insulin Initialization and Titration in People With Type 2 Diabetes Wearing a Dexcom G6 Sensor

Evaluation of Basal Insulin Initialization and Titration in People With Type 2 Diabetes Wearing a Dexcom Sensor

To evaluate the feasibility of the DexBasal Study System

To evaluate the feasibility of the DexBasal Study System for recommending doses of basal insulin, embodied as a clinician facing Web portal.

Inclusion Criteria: Patients with a diagnosis of Type 2 diabetes (T2D) mellitus

• Ages equal or greater 18 years ("age" determined at the time of the Screening Visit)
• Bodyweight between 30-450 kg
• Comfortable with and willing to administer basal insulin injections, once a day, for approximately 75 consecutive days, and log daily injections in the Dexcom CGM mobile application.
• Willing to wear Dexcom CGM for duration of study

Exclusion Criteria:

• Recent severe hypoglycemia, complicated by seizure(s) or loss of consciousness, in the past 3 months
• Subjects with any contraindications for starting or continuing basal insulin therapy
• Glomerular filtration rate (eGFR) < 30 ml/min/1.73m2 (within 6 months of insertion) or on hemodialysis
• Introducing or increasing glucose lowering medications simultaneously
• Any condition that, in the opinion of the Investigator, would interfere with a subject's participation in the trial or pose excessive risk to subject and/or study staff
• For subjects of child-bearing potential: Pregnancy, demonstrated by a positive test no more than 72 hours prior to Clinic Visit 1
• Has used prandial insulin in the last 30 days.
• Anticipated addition of medications that could have significant impact on insulin sensitivity such as atypical antipsychotics.